MONTREAL, Nov. 16, 2011 /CNW Telbec/ - Sunshine Biopharma Inc. (OTCBB:
SBFM) a development stage pharmaceutical company focused on the
research, development and commercialization of drugs for the treatment
of various forms of cancer, today announced that it has successfully
completed the preclinical studies for Adva-27a, the Company's lead
oncology drug candidate. Adva-27a was found to have unique
pharmaceutical properties of substantial clinical interest. In
summary, the results to date have shown that:
Adva-27a is 16-times more effective at killing multidrug resistant
breast cancer cells than Etoposide, the drug currently in use.
Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for
making cancer cells resistant to anti-tumor drugs.
Adva-27a has excellent clearance time (half-life = 54 minutes) as
indicated by human microsomes stability studies.
Adva-27a clearance is independent of Cytochrome P450, a mechanism that
is less likely to produce toxic intermediates.
Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of
only 13.7 micromolar.
Adva-27a has shown excellent pharmacokinetics profile as indicated by
studies done in rats.
Adva-27a's initial indication will be multidrug resistant breast cancer
for which there are little or no treatment options.
"We are now ready to move to the next stage in our Adva-27a drug
development program," said Dr. Steve N. Slilaty, President and CEO of
Sunshine Biopharma. "In this stage we will conduct GMP manufacturing
of Adva-27a and then use the material to perform the so-called
IND-enabling studies, following which we will file our IND Application
and proceed to doing Phase I clinical trials," he added. Dr. Slilaty
also stated, "We are delighted to have completed this milestone and are
looking forward to the challenges ahead leading to our ultimate goal of
improving the quality of life for cancer sufferers."
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly
historical, including statements as to revenue projections, business
strategy, outlook, objectives, future milestones, plans, intentions,
goals, future financial conditions, future collaboration agreements,
the success of the Company's development, events conditioned on
stockholder or other approval, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made.
SOURCE SUNSHINE BIOPHARMA INC.
For further information:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464